Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS Press Releases

  • DNDi agreement with Colombia Ministry of Health and Social Welfare to guarantee access to comprehensive care for Chagas patients
  • Drug approved in Argentina for treatment of Chagas disease in children
  • Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa
  • New affordable hepatitis C combination treatment shows 97% cure rate
  • Takeda Pharmaceutical and DNDi collaborate to progress a potential new drug for visceral leishmaniasis through the R&D pipeline

RSS In the Media

  • Caracol Radio: “Minsalud desarrolla acuerdo para garantizar la atención integral de Chagas”
  • Al Quds: “دواء يشÙ�ÙŠ Ù�يروس “سي” بنسبة %96″
  • Digital Journal: “Affordable hepatitis C treatment close to launch”
  • Gigazine: “高価ã�ªã€ŒCåž‹è‚�炎治療薬ã€�ã�®åŠ¹æžœã‚’ä¿�ã�£ã�Ÿã�¾ã�¾å®‰ä¾¡ã�§æ��ä¾›ã�™ã‚‹ã�Ÿã‚�ã�®å�–り組ã�¿ã�Œé€²è¡Œä¸­”
  • Infobae: “Día Mundial del Chagas: ‘Aún no se detecta al 50 por ciento de los bebés que nacen con Chagas'”

RSS Scientific Articles

  • Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind
  • In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series
  • Report of the first international workshop on onchocerciasis-associated epilepsy
  • Evaluation of a pan-Leishmania spliced-leader RNA detection method in human blood and experimentally infected Syrian golden hamsters
  • Development of (6R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (DNDI-8219): A new lead for visceral leishmaniasis

RSS News

  • DNDi welcomes Astellas to the NTD Drug Discovery Booster
  • DNDi welcomes GHIT support for a new collaboration on natural products with Daiichi Sankyo RD Novare
  • R&D Portfolio Update March 2018: DNDi Sleeping sickness programme
  • R&D Portfolio Update March 2018: DNDi Leishmaniasis programme
  • R&D Portfolio Update March 2018: DNDi Chagas disease programme

RSS Events

  • 22nd International AIDS Conference
  • Biotech Outsourcing Strategies 2018
  • XXXVI Congreso Nacional de Cardiología 2018
  • MSF Scientific Days 2018
  • 28th European Congress of Clinical Microbiology and Infectious Diseases

RSS Scientific Articles

  • Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind
  • In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series
  • Report of the first international workshop on onchocerciasis-associated epilepsy
  • Evaluation of a pan-Leishmania spliced-leader RNA detection method in human blood and experimentally infected Syrian golden hamsters

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

 

Subscribe

Sign up for the E-news newsletter

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website
  • GARDP

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

Graphic of DNDi's social mission ratio

  • TERMS OF USE
  • PRIVACY POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License